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The multicenter, single-arm BONAFIDE study characterized
the skeletal response to cinacalcet in adult dialysis patients
with plasma parathyroid hormone (PTH) levels of 300pg/ml
or more, serum calcium of 8.4mg/dl or more, bone-specific
alkaline phosphatase over 20.9 ng/ml and biopsy-proven
high-turnover bone disease. Of 110 enrolled patients,
77 underwent a second bone biopsy with quantitative
histomorphometry after 6–12 months of cinacalcet treatment.
The median PTH decreased from 985pg/ml at baseline to
480pg/ml at the end of study (weeks 44–52). Bone formation
rate/tissue area decreased from 728 to 336lm2/mm2/day,
osteoblast perimeter/osteoid perimeter decreased from 17.4
to 13.9%, and eroded perimeter/bone perimeter decreased
from 12.7 to 8.3%. The number of patients with normal bone
histology increased from none at baseline to 20 at 12
months. Two patients had adynamic bone at the end of
study with a PTH under 150pg/ml, and one patient
with overt hypophosphatemia at baseline that reoccurred
during follow-up developed osteomalacia. Thus, long-term
treatment with cinacalcet substantially reduced PTH,
diminished the elevated bone formation rate/tissue area,
lowered several biochemical markers of high-turnover bone
disease toward normal, and generally improved bone
histology. Twenty patients had normal bone histology at
follow-up, whereas most had mild hyperparathyroidism
or mixed uremic osteodystrophy.
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Bone disease is a major consequence of secondary hyper-
parathyroidism (sHPT) among patients with chronic kidney
disease (CKD). It is an integral component of the syndrome
of CKD–mineral and bone disorder affecting a substantial
proportion of patients undergoing dialysis. The skeletal
manifestations of sHPT arise largely from the ongoing release
of excess amounts of parathyroid hormone (PTH) into the
circulation by enlarged parathyroid glands.1 Accordingly,
serum or plasma PTH levels are elevated, often markedly so.
A key objective in the treatment of sHPT is to lower PTH
levels toward recommended target ranges and to correct the
histopathological changes of sHPT in bone.2
Vitamin D sterols and calcimimetic agents are the
only two pharmacological interventions available currently
to lower PTH levels among patients with sHPT managed
with dialysis. Treatment with vitamin D sterols has been
shown to reduce PTH, mostly in small studies lasting
several weeks or only a few months.3,4 The PTH-lowering
effect of the calcimimetic agent cinacalcet (Sensipar/
Mimpara) is recognized generally,5–7 and clinical outcomes
after prolonged treatment were reported recently.8 Much less
is known, however, about changes in bone histology after
prolonged therapy with either vitamin D or cinacalcet.
Some improvements in bone histology have been described
in small studies after treatment with daily oral doses or thrice
weekly intravenous doses of calcitriol in adults with sHPT
undergoing hemodialysis.9,10 Similar findings were reported
after treatment with oral or intraperitoneal doses of calcitriol
or with oral doses of doxercalciferol in pediatric patients
receiving peritoneal dialysis.11 With regard to cinacalcet,
modest improvement in the histological features of sHPT and
decreases in bone turnover were noted in one small study after
12 months of treatment,12 but the effect of cinacalcet on renal
bone disease among patients undergoing dialysis has yet to be
characterized adequately. Of note, the exploratory end point
of fracture rate did not differ in unadjusted analyses in the
EVOLVE outcomes study among subjects assigned randomly
to treatment with cinacalcet or placebo.8
The purpose of the BONAFIDE study described herein
was to further assess the skeletal response to cinacalcet
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treatment among patients with histological evidence of
hyperparathyroid bone disease. Bone biopsy and quanti-
tative bone histomorphometry were done before and
after treatment. Various biochemical parameters of mineral
metabolism were measured at baseline and at regular
intervals during follow-up.
RESULTS
One hundred and forty-six (146) adult dialysis patients with
plasma PTH (PTH)X300 pg/ml, serum calciumX8.4mg/dl,
and bone-specific alkaline phosphatase (BALP) 420.9 ng/ml
underwent bone biopsy during screening (Figures 1 and 2).
The biopsy sample was inadequate for histomorphometric
evaluation in 11 cases, and 25 subjects were excluded from
further study because they did not have biopsy findings
consistent with hyperparathyroid bone disease as specified
in the study protocol (Figure 2). Notably, 22 of these had
normal bone histology and 3 had mixed lesions of renal
osteodystrophy, whereas none had adynamic bone.
Of 110 subjects who entered into the single-arm study and
were treated with cinacalcet at a starting dose of 30mg/day,
70 (64%) were men and 91 (83%) were Caucasian. The mean
(s.d.) age was 55.2 (14.2) years, range 19–82 years, and the
median (interquartile range; IQR) hemodialysis vintage was
43.0 (17.0, 89.0) months. At baseline, 59 subjects (54%) were
receiving a vitamin D sterol and 92 (84%) were receiving a
phosphate-binding agent and/or calcium supplement. None
had been treated previously with cinacalcet.
Eighty-four subjects completed the study and 77 under-
went a follow-up bone biopsy that provided tissue sufficient
for quantitative histomorphometry (Figure 2). All but three
subjects were biopsied after approximately 12 months
of treatment with cinacalcet. In two subjects, treatment
with cinacalcet was stopped after 6 months, and follow-up
biopsies were obtained at month 7 in one and at month 8
in the other. A third subject was treated with cinacalcet for
3 months but did not have a follow-up biopsy until
month 12. All final results are based upon the 77 subjects
with bone biopsy data at baseline and follow-up (Tables 1 and
2). Demographic and biochemical results at baseline for the 33
subjects who did not have paired biopsy specimens before and
after treatment also are provided for comparison (Table 3).
The mean (s.d.) daily doses of cinacalcet among the 77
patients at the end of the titration (week 20), maintenance
(week 40), and efficacy assessment phases (week 52) were
67.5 (40.7), 72.3 (46.6), and 73.2 (43.9) mg/day, respectively.
Reasons for cinacalcet discontinuation varied as expected
(Table 4). Of the 77 subjects, 39 (51%) were receiving
vitamin D at baseline and 60 (78%) received vitamin D
at some point during the study. The mean (s.d.) weekly
dose of vitamin D ranged from 15.9 (10.1) to 21.8 (21.2) mg
expressed in mg equivalents of paricalcitol. The types of
vitamin D used included oral alfacalcidol only (n¼ 3), oral
calcitriol only (n¼ 14), doxercalciferol only (n¼ 4), parical-
citol only (n¼ 21), and other/multiple vitamin D (n¼ 14).
The median (IQR) PTH at baseline was 985 (674, 1621)
pg/ml, and values decreased nominally to 480 (268, 798) pg/
ml, or by a median (IQR) percent change of  48.3%
( 68.8%,  26.5%), after treatment with cinacalcet,
Po0.001 (Figure 3).
Bone histomorphometry
The primary study end point was the change in bone
formation rate/tissue area (BFR/T.Ar) from baseline to
follow-up during treatment with cinacalcet. The median
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Figure 1 | Study design and treatment schema.
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Figure 2 | Subject disposition by treatment phase.
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(IQR) value for BFR/T.Ar at baseline exceeded the upper
limit of the normal reference range (97–613 mm2/mm2/day),13
but it decreased from 727.8 (545.9, 1052.6) to 336.1 (172.2,
641.8) mm2/mm2/day at end of study (EOS), Po0.0001
(Figure 4; Table 1). The change in BFR/T.Ar during treatment
was greater among subjects with baseline PTH concentrations
4800 pg/ml (n¼ 52) compared with those with results
p800 pg/ml (n¼ 25); median (IQR) changes were  507
( 748.1,  276.1) mm2/mm2/day and  200 ( 369.5, 26.1)
mm2/mm2/day, respectively. Subjects who experienced reduc-
tions in BFR/T.Ar (n¼ 65) during treatment had higher
median (IQR) values at baseline, 816 (595, 1262) mm2/mm2/
day, compared with the 12 subjects who did not have a
decrease in BFR/T.Ar during follow-up, 425 (154, 592) mm2/
mm2/day. The median (IQR) PTH level at baseline also was
higher in subjects who had a decrease in BFR/T.Ar during
treatment than in those who did not; values were 1113 (693,
1675) and 622 (454, 1110) pg/ml, respectively, at baseline
and 536 (313, 959) and 352 (193, 917) pg/ml, respectively,
at follow-up in these two groups.
Several static histomorphometric measures of bone
formation and bone resorption were elevated at baseline
but decreased toward normal during treatment (Table 1).
The median (IQR) change for osteoblast perimeter (Ob.Pm/
O.Pm) was  3.8% ( 9.7%, 1.7%), Po0.001, for osteoclast
perimeter (Oc.Pm/E.Pm) was  2.1% ( 10.6%, 5.8%),
P¼ 0.062, and for eroded perimeter (E.Pm/B.Pm) was
 3.4% ( 6.9%, 0.1%), Po0.001. Bone area/tissue area
(B.Ar/T.Ar) did not differ at follow-up compared with
baseline. The number of subjects with no peri-trabecular or
marrow fibrosis increased from 6 (8%) at baseline to 24
(31%) at EOS (Table 1). Of 71 subjects (92%) with fibrosis
at baseline, 21 (27%) had complete resolution at follow-up.
The distribution of the various types of renal osteo-
dystrophy changed substantially during the study (Figure 5).
At baseline, most subjects had either mild or severe hyper-
parathyroid bone disease. At EOS, the number of subjects
with severe hyperparathyroid bone disease decreased sub-
stantially from 13 to 3. Normal bone histology was found in
20 subjects (26%) overall.
The number of subjects with mixed uremic osteodystro-
phy increased from 8 at baseline to 18 at EOS. These subjects
Table 1 | Bone histomorphometrya before and after treatment with cinacalcet
Baseline, median (IQR) End of study, median (IQR) P-valueb
B.Ar/T.Ar (%) [14.6–26.9] 24.3 (20.2, 30.7) 25.3 (20.2, 29.8) 0.54
O.Ar/B.Ar (%) [0.2–5.8] 5.1 (3.5, 7.4) 3.8 (2.4, 6.6) 0.072
O.Pm/B.Pm (%) [10.2–31.7] 40.1 (30.3, 50.7) 30.7 (21.4, 46.3) 0.003
O.Wi (mm) [4.1–13.1] 9.6 (8.1, 12.3) 10.3 (7.9, 14.0) 0.17
Ob.Pm/O.Pm (%) [1.8–58.3] 17.4 (11.8, 26.0) 13.9 (6.2, 25.0) o0.001
dL.Pm/B.Pm (%) [1.6–15.8] 14.5 (9.7, 21.3) 8.1 (4.3, 15.0) o0.001
E.Pm/B.Pm (%) [0.4–3.4] 12.7 (9.9, 16.4) 8.3 (6.2, 12.7) o0.001
Oc.Pm/E.Pm (%) [0.4–3.4] 20.4 (13.2, 27.2) 18.0 (13.9, 22.3) 0.062
Tb.Wi (mm) [90–175] 145.5 (124.6, 168.8) 153.6 (129.7, 174.6) 0.25
Tb.N (mm) [1.1–2.2] 2.2 (1.8, 2.6) 2.1 (1.8, 2.4) 0.19
BFR/T.Ar (mm2/mm2/day) [97–613] 727.8 (545.9, 1052.6) 336.1 (172.2, 641.8) o0.0001
Mlt (days) [2.4–63] 17.8 (10.9, 26.3) 21.4 (14.7, 44.0) o0.001
Fb.Ar/T.Ar n (%) n (%)
0% 6 (8%) 24 (31%)
1–5% 50 (65%) 42 (55%)
6–10% 18 (23%) 9 (12%)
11–25% 1 (1%) 2 (3%)
425% 2 (3%) 0
Abbreviations: B.Ar, bone area; B.Pm, bone perimeter; dL.Pm, double labeled perimeter; E.Pm, eroded perimeter; Fb.Ar, fibrosis area; Mlt, mineralization lag time; O.Ar,
osteoid area; Ob.Pm, osteoblast perimeter; Oc.Pm, osteoclast perimeter; O.Pm, osteoid perimeter; O.Wi, osteoid width; T.Ar, tissue area; Tb.N, trabecular number; Tb.Wi,
trabecular width.13,14
Continuous variables are presented as median values with interquartile range (IQR). Numbers in [brackets] denote the lower and upper limit of values for subjects with
normal kidney function.13–15
aResults are formatted for two dimensions.
bDescriptive P-values were obtained from the Wilcoxon signed-rank test.
Table 2 | Biochemical measurements before and after
treatment with cinacalcet
Baseline,
median (IQR)
End of studya,
median (IQR) P-valueb
PTH (pg/ml) c [10–65] 985 (674, 1621) 480 (268, 798) o0.001
Calcium (mg/dl) [8.4–10.3] 9.9 (9.4, 10.3) 9.1 (8.6, 9.7) o0.001
Phosphorus (mg/dl) [2.2–5.1] 5.5 (4.7, 6.2) 5.5 (4.9, 6.6) 0.94
Ca x P (mg2/dl2) [18.5–52.5] 53.8 (46.6, 63.9) 52.6 (43.2, 62.2) 0.050
BALP (ng/ml) [2.9–22.4] 40.1 (27.3, 73.9) 27.7 (18.8, 53.9) 0.20
N-telopeptide (nmol/l)
[5.4–24.2]
378 (169, 1304) 249 (126, 425) o0.001
TRAP (U/l) [0.49–5.31] 6.8 (5.1, 9.3) 5.1 (3.8, 7.2) 0.003
Osteocalcin (ng/ml) [11–55.9] 494 (245, 846) 276 (151, 526.) o0.001
Abbreviations: BALP, bone-specific alkaline phosphatase; IQR, interquartile range;
PTH, parathyroid hormone; TRAP, tartrate-resistant acid phosphatase.
Numbers in [brackets] denote the lower and upper limit of values for subjects with
normal kidney function.
aThe end of study value for biochemical parameters is defined as the mean value
during the efficacy assessment phase (week 44–52).
bDescriptive P-values were obtained from the Wilcoxon signed-rank test.
cValues from 74 subjects with measurements both at baseline and at end of study.
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generally had a normal BFR/T.Ar with fibrosis but without
evidence of impaired mineralization (type 2), which is
generally associated with mixed lesions of type 1. Indeed,
BFR/T.Ar at EOS was normal (combined with fibrosis) in 13
subjects with mixed lesions, of whom 10 showed an osteoid
area o12%. Two subjects with mixed lesions at follow-up
had BFR/T.Ar values below the lower limit of normal but also
had fibrosis.
Two subjects had adynamic bone and one had osteoma-
lacia on follow-up bone biopsy (vide infra). None of the
subjects showed positive aluminum staining on bone biopsy.
Although biopsies were categorized into the various types
of renal osteodystrophy using reference values for BFR/T.Ar
obtained originally from children and adolescents, the
results did not differ materially when assessed using
published values for BFR/T.Ar from adults (Supplementary
Figure S1 online).
Biochemistry
As stated previously, PTH levels decreased significantly
during treatment with cinacalcet. The changes in PTH
(Table 2, Figure 3) correlated positively with changes in BFR/
T.Ar (rs: 0.344; P¼ 0.003), E.Pm/B.Pm (rs: 0.310, P¼ 0.007),
and trabecular number (rs: 0.318; P¼ 0.006). Serum calcium
and Ca x P values were lower compared with baseline during
the efficacy assessment phase of the study. The mean (s.e.)
Table 3 | Demographic and biochemical characteristics at baseline for subjects with or without bone histomorphometry results
after treatment with cinacalcet
Subjects included in final analysis (n¼ 77) Subjects excluded from final analysis (n¼ 33)
Male sex, n (%) 53 (69) 17 (52)
White race, n (%) 63 (82) 28 (85)
Mean (s.d.) age [range], years 54.5 (13.6) [26, 82] 56.8 (15.7) [19, 80]
Mean (s.d.) height, cm 168 (10) 167 (10)
Mean (s.d.) weight, kg 73.7 (17.8) 71.6 (18.6)
Dialysis duration, median (IQR)
Hemodialysis, months 43 (17, 89) [n¼ 73] 43 (20, 117)
Peritoneal dialysis, months 37 (16, 53) [n¼ 4] —
Use of phosphate binder/calcium supplement, n (%) 65 (84) 27 (82)
Lab values, median (IQR)
PTH, pg/ml 997 (674, 1621) 1322 (752, 2063)
Calcium, mg/dl 9.9 (9.4, 10.3) 10.1 (9.8, 10.5)
Phosphorus, mg/dl 5.5 (4.7, 6.2) 5.7 (5.0, 6.5)
Ca x P (mg2/dl2) 53.8 (46.6, 63.9) 58.6 (50.6, 65.0)
BALP, ng/ml 40.1 (27.3, 73.9) 47.5 (28.8, 74.1)
N-telopeptide, nmol/l 378 (169, 1304) 1041 (277, 1691)
TRAP, U/l 6.8 (5.1, 9.3) 6.9 (4.0, 10.9)
Osteocalcin, ng/ml 494 (245, 846) 671 (373, 1038)
Abbreviations: BALP, bone-specific alkaline phosphatase; IQR, interquartile range; PTH, parathyroid hormone; s.d., standard deviation; TRAP, tartrate-resistant acid
phosphatase.
Table 4 | Reasons for cinacalcet discontinuation
No. of subjects (%)
Subjects enrolled 110
Subjects who received cinacalcet 110 (100)
Subjects who completed the study 84 (76)
Subjects who completed cinacalcet treatment 69 (63)
Subjects who discontinued cinacalcet 41 (37)
Adverse event 2 (2)
Consent withdrawn 4 (4)
Administrative decision 1 (1)
Lost to follow-up 2 (2)
Death 5 (5)
Protocol-specified criteria 13 (12)
Patient request 1 (1)
Other reason 13 (12)
Percentages based on number of subjects enrolled.
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Figure 3 | Comparison of PTH level at baseline and efficacy
assessment phase (median-IQR-range). P-value: Wilcoxon-signed
rank test.
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changes were  7% (1.1%) and  6.9% (3.1%), respectively.
Serum phosphorus levels did not differ.
Values for two biochemical markers of resorption,
N-telopeptide (NTx) and tartrate-resistant acid phosphatase
(TRAP), and for the bone formation marker osteocalcin
(OC) were elevated at baseline but decreased at follow-up
(Table 2). The median (IQR) percent changes from baseline
to week 52 were  39.1% ( 62.5%,  13.9%), Po0.001,
for OC,  31.6% ( 56.0%, 4.1%), Po0.001, for NTx, and
 19.9% ( 39.7%, 10.0%), P¼ 0.003, for TRAP. No notable
change in BALP was observed.
In the subset of 20 subjects who had normal bone
histology at follow-up, median (IQR) PTH values decreased
from 884 (603, 1323) to 283 (164, 453) pg/ml (Table 5). The
mean percentage changes in NTx, TRAP, and OC in these
subjects were somewhat greater compared with the overall
treatment group.
Safety evaluation
A total of 110 subjects received more than one dose of
cinacalcet and were included in the safety population. The
mean (s.d.) daily dose of cinacalcet at the end of the titration,
maintenance, and efficacy assessment phases was 74.1 (43.6),
75.2 (49.4), and 75.0 (45.5) mg/day, respectively.
The most common adverse events (AEs) were nausea
(26%), vomiting (21%), diarrhea (20%), arthralgia (14%),
hypocalcemia (12%), dyspnea (11%), and muscle spasms
(11%). Treatment-related AEs were reported in 47 subjects
(43%); these included nausea in 16 (15%), symptomatic
hypocalcemia in 12 (11%), vomiting in 10 (9%), dyspepsia in
9 (8%), and diarrhea in 7 (6%). Three subjects had serious
treatment-related AEs: symptomatic hypocalcemia, convul-
sion, and convulsion and symptomatic hypocalcemia,
respectively. There were no deaths or life-threatening AEs
that were judged to be related to cinacalcet. Only two subjects
(2%) had AEs that led to discontinuation of cinacalcet and
one subject had an AE that led to withdrawal from the study.
Overall, for the safety population, the mean (s.d.) serum
calcium was 10.0 (0.7) mg/dl at baseline, 9.1 (0.9) mg/dl at
week 20, and 9.2 (0.9) mg/dl at week 52. The mean (s.e.)
percent change from baseline in serum calcium ranged from
 11.1% (0.9%) to  5.7% (1.1%) over the course of the
study.
Safety end points for bone mineralization were evaluated
by comparing biopsy results at screening and at EOS.
Mineralization lag time was highly skewed by extreme values
resulting from sample testing, the median (IQR) mineraliza-
tion lag time at baseline and at EOS was 18 (11, 26) and 21
(15, 44) days, respectively.
Double labeled perimeter/bone perimeter (dL.Pm/B.Pm)
at baseline was within normal limits in 27 subjects (35%) and
elevated in 50 subjects (65%). At EOS, values remained
within the normal range in 22 subjects, decreased from
elevated values to normal in 28 subjects, and remained
elevated in 22 subjects. In the five remaining subjects with
initially normal values for dL.Pm/B.Pm, results at follow-up
were elevated in four and low in one. Overall, median (IQR)
osteoid area/bone area (O.Ar/B.Ar) was unchanged from
baseline to EOS with values of 5.1% (3.5%, 7.4%) and 3.8%
(2.4%, 6.6%), respectively. This parameter was normal at
baseline in 41 subjects (53%) and remained normal in 31
subjects (40%) at EOS. Values were normal initially and
became elevated in 10 subjects (13%) and decreased from
elevated values to normal in 20 subjects (26%), whereas
O.Ar/B.Ar was elevated both at baseline and at EOS in 16
subjects (21%).
Two subjects developed adynamic bone as documented by
EOS bone biopsy findings of O.Ar/B.Ar o12%, BFR/T.Ar
o97 mm2/mm2/day, and no evidence of fibrosis. Both
subjects had risk factors for adynamic bone that included a
normal BFR/T.Ar at baseline with values of 385 and 398 mm2/
mm2/day, respectively, and only minimal signs of fibrosis that
supported a study diagnosis of hyperparathyroid bone
disease. Both subjects received calcium-containing phosphate
binders and had PTH values p100 pg/ml during the study
that required reductions in the dose of cinacalcet. At EOS,
BFR/T.Ar was low but measureable with values of 25 and
32 mm2/mm2/day, respectively. One patient had a PTH of
331 pg/ml at screening that decreased to 198 pg/ml prior to
the start of cinacalcet. Treatment was finally withdrawn at
week 45 because PTH levels were persistently o150 pg/ml.
BALP also decreased from 21.5 to 14.6 ng/ml during the
study. Advanced age, type 2 diabetes, and treatment with a
vitamin D sterol were additional potential contributors. In
the other patient, PTH decreased from 711 to 236 pg/ml and
BALP decreased from 63.2 to 9.3 ng/ml over the course of the
study, but PTH was as low as 106 pg/ml during the titration
phase.
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Figure 4 | Primary efficacy end point: comparison of BFR/T.Ar
(median-IQR-range) at baseline and end of study. P-value:
Wilcoxon signed-rank test. BFR, bone formation rate; T.Ar, tissue area.
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An additional subject developed osteomalacia. At baseline,
bone biopsy showed mild hyperparathyroid bone disease
with BFR/T.Ar of 697 mm2/mm2/day, E.Pm/B.Pm of 11.5%,
and some fibrosis (1–5%). At EOS, fibrosis area was
unchanged, but BFR/T.Ar decreased to 71 mm2/mm2/day
and E.Pm/B.Pm decreased to 2.4%. Mineralization lag time
increased from 36 days at baseline to 894 days at follow-up,
and O.Ar/B.Ar increased from 5.0% to 30.8%. Overt
hypophosphatemia was present both at baseline and
recurrently during follow-up.
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Mixed uremic osteodystrophy
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Mixed uremic osteodystrophy
Normal bone histology
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Figure 5 | Evolution of type of renal osteodystrophy after cinacalcet treatment.
Table 5 | Biochemical measurementsa in subjects who did or did not have normal bone histology at follow-up
Normal histology (n¼ 20) Abnormal histology (n¼ 57)
Baseline End of study Baseline End of study
PTH (pg/ml) [10–65] 884 (603, 1323) 283 (164, 453) 1124 (681, 1716) 606 (319, 1022)
BALP (ng/ml) [2.9–22.4] 36.6 (27.6, 53.0) 18.9 (13.7, 25.0) 45.3 (27.3, 90.9) 34.2 (20.6, 82.8)
N-telopeptide (nmol/l) [5.4–24.2] 253 (166, 464) 133 (60, 251) 540 (169, 1364) 303 (167, 762)
TRAP (U/l) [0.49–5.31] 5.7 (4.1, 8.6) 4.1 (3.0, 5.3) 7.1 (5.2, 9.4) 5.4 (4.1, 7.8)
Osteocalcin (ng/ml) [11–55.9] 296 (215, 480) 156 (107, 234) 580 (303, 906) 366 (195, 633)
Abbreviations: BALP, bone-specific alkaline phosphatase; PTH, parathyroid hormone; TRAP, tartrate-resistant acid phosphatase.
Numbers in [brackets] denote the lower and upper limit of values for subjects with normal kidney function.
aData are presented as median (interquartile range).
Kidney International (2015) 87, 846–856 851
GJ Behets et al.: Bone histomorphometry changes with cinacalcet c l i n i ca l t r i a l
DISCUSSION
Cinacalcet has been shown to lower plasma PTH levels in a
number of clinical trials among patients undergoing
dialysis,5–7 but the effects of treatment on the histological
features of sHPT in bone have not been characterized
adequately. The BONAFIDE study was designed to address
this matter prospectively in a multicenter, single-arm, open-
label trial. Treatment with cinacalcet for at least 6 months
decreased the initially elevated mean value for BFR/T.Ar
toward normal and reduced mean values for other
parameters of bone histomorphometry that are typically
abnormally high in patients with established sHPT. The
observed changes in bone histology corresponded with
interval reductions in PTH levels and with decreases in the
serum concentrations of several biochemical markers of bone
turnover.
Of 146 subjects with PTHX300 pg/ml, BALP420.9 ng/ml,
and calcium X8.4mg/dl who underwent bone biopsy,
25 were excluded from study because they did not have
histomorphometric evidence of high-turnover bone disease, a
cardinal feature of sHPT. This finding is consistent with
reports from others that have highlighted the limitations of
using a single PTH measurement to differentiate between
high-turnover and low-turnover skeletal lesions of renal
osteodystrophy.14,15 Indeed, reliance upon single PTH and
BALP values rather than two or more measurements of each
parameter on separate days to determine subject eligibility
for the current study represents a potential shortcoming of
the project. Nevertheless, the observation that no cases
of adynamic bone were identified among subjects with PTH
X300 pg/ml and BALP 420.9 ng/ml in this large multi-
center bone biopsy study suggests that adynamic renal
osteodystrophy is highly unlikely among dialysis patients
with this combination of biochemical findings.
During treatment with cinacalcet, there was a significant
decrease in PTH from baseline, Po0.001, together with a
substantial reduction in BFR/T.Ar. The changes in BFR/T.Ar
were most pronounced among subjects with baseline PTH
values4800 pg/ml. The strength of the relationship between
changes in PTH and BFR/T.Ar during treatment was only
modest as documented by the Spearman rank correlation
coefficient of 0.344. Baseline median (IQR) values for BFR/
T.Ar were higher among subjects who experienced a
reduction in bone formation during treatment compared
with those who did not, 816 (595, 1262) vs. 425 (154, 592)
mm2/mm2/day. Such findings suggest that the likelihood
of developing low-turnover skeletal lesions or adynamic
bone is low among patients with CKD undergoing dialysis
when cinacalcet is used to treat sHPT for as long as
12 months.
Of 71 subjects with evidence of peri-trabecular and/or
marrow fibrosis at baseline, 21 had complete resolution of
this finding at follow-up. Twenty subjects had normal bone
histology at the follow-up biopsy. The median (IQR) PTH in
these 20 subjects decreased from 884 (603, 1323) pg/ml at
baseline to 283 (164, 453) pg/ml at follow-up, and median
(IQR) BALP decreased from an initially elevated level of 36.6
(27.6, 53.0) ng/ml to 18.9 (13.7, 25.0) ng/ml, a value within
normal limits. The serum concentrations of NTx, OC, and
TRAP also decreased during treatment in this subgroup to
levels that approached the normal range.
Bone mineralization was assessed by measuring miner-
alization lag time, O.Ar/B.Ar, and osteoid seam width. Values
for mineralization lag time are high in patients with
osteomalacia, in many cases of mixed uremic osteodystrophy,
and in patients with adynamic bone.16 In the current study,
median (IQR) mineralization lag time increased slightly from
18 (11, 26) days to 21 (15, 44) days, a change consistent
with the observed reduction in BFR/T.Ar. Median values
for O.Ar/B.Ar and for osteoid seam width did not increase
during treatment. Accordingly, the use of cinacalcet to
lower PTH levels in the current study reduced bone
formation and turnover without adversely affecting skeletal
mineralization.
The large number of subjects classified as having mixed
uremic osteodystrophy reflects the relatively broad criteria
used by the pathologist to define subjects with mixed lesions,
i.e., subjects showing the classical picture of normal or
high turnover in combination with a mineralization defect
(type 1), as well as those showing normal bone turnover and
fibrosis in the absence of a mineralization defect (type 2).
Elevated values for dL.Pm/B.Pm, a finding consistent
with high-turnover bone disease, were present in 65% of
subjects at baseline but became normal in 56% (28/50) of
these subjects at EOS. Such results are common among
patients treated medically for sHPT. Changes in other
secondary study end points that included several biochemical
markers of bone turnover such as BALP, OC, NTx, and
TRAP further suggest a favorable effect of cinacalcet therapy
on bone formation and turnover among patients with
sHPT.
Two subjects had BFR/T.Ar values below the lower limit of
normal and other histomorphometric findings consistent
with adynamic bone after 12 months of treatment with
cinacalcet. Both had risk factors for adynamic bone at
baseline; these included diabetes in one and advanced age
exceeding 80 years in the other. Additional contributory
factors in each case included concurrent treatment with
calcium-containing phosphate-binding agents and vitamin D
analogs. Notably, BFR/T.Ar was within the normal range at
baseline in both subjects, and both developed PTH
concentrations o150 pg/ml during the study. Very low
PTH levels were seen on several occasions in one case,
requiring reductions in the dose of cinacalcet. Cinacalcet
therapy was withdrawn in the other subject because PTH
values remained persistently below 150 pg/ml.
Such findings underscore the importance of regularly
monitoring PTH levels and appropriately adjusting doses of
cinacalcet, vitamin D, and/or calcium as needed to avoid
lowering PTH levels excessively during the treatment of
sHPT. Adynamic bone is seen most often among patients
with CKD who have persistently low PTH levels, but the
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disorder can be corrected when measures that suppress
parathyroid gland function are modified or withdrawn.17,18
In this regard, the half-life of cinacalcet in serum is relatively
short with an average of 32 hours, and plasma PTH levels
increase within a few days after daily doses of cinacalcet
are withheld.19 The capacity to correct parathyroid gland
suppression and to allow PTH levels to rise after treatment
with cinacalcet is interrupted thus diminishes the risk of
developing adynamic bone when therapy is monitored
appropriately. Apart from measurements of PTH,20,21 low
levels of BALP (p10 ng/ml) provide an additional
biochemical marker of adynamic bone among patients
undergoing hemodialysis.14,15,22
An additional subject in the current study developed
osteomalacia during treatment with cinacalcet. Aluminum
staining was negative on bone biopsy. For reasons that are
unclear, serum phosphorus concentrations at baseline were
low, and episodes of hypophosphatemia occurred repeatedly
during follow-up, findings distinctly unusual in the setting of
dialysis. Hypophosphatemia is a recognized cause of osteo-
malacia, and its presence should have precluded entry of this
subject into the study.
Of the 110 subjects enrolled, 84 (76%) completed the
study and 26 (24%) discontinued the study, most commonly
(n¼ 11) for protocol-specified criteria including para-
thyroidectomy, renal transplantation, AEs, or persistent
hypocalcemia. Seventy-seven subjects successfully underwent
a follow-up bone biopsy with quantitative histomorphometry
after receiving at least 6, but no more than 12, months of
cinacalcet treatment. The AEs reported in this study were
generally mild or moderate and similar to those reported
in other cinacalcet clinical trials in adult patients. Only
2 subjects (2%) had AEs that led to discontinuation of
cinacalcet and 1 patient had an AE that led to withdrawal
from the study.
A limitation of the current study is the inability to
determine how much of the treatment effect was attributable
to cinacalcet and how much to vitamin D. In randomized
trials that have compared treatment with cinacalcet or
vitamin D where most subjects were receiving vitamin D at
baseline, the effect of treatment on biochemical parameters
has been greater in the cinacalcet arm.7,23,24 In the current
study, many subjects in the efficacy analysis set were receiving
vitamin D at baseline and most received vitamin D during
the study, so the primary change was the use of cinacalcet.
This suggests that most of the observed effect on bone was
due to cinacalcet, but the study was not designed to answer
this question.
A second potential limitation of the study is the use of
reference data for bone histomorphometry generated origin-
ally in biopsy specimens obtained from healthy children
and adolescents to assess biopsies from older adult subjects
with sHPT undergoing dialysis. Although the rates of bone
formation and remodeling may be modestly higher in
younger persons than in adults, there is considerable overlap
among values as determined using the technique of double
tetracycline-labeling in cancellous bone from the iliac
crest.25,26 In this regard, only modest differences in the
distribution of subjects according to various types of renal
bone disease were observed when published values for BFR/
T.Ar in adults were used separately to categorize subjects
in the current study both at baseline and at EOS. In addition,
any purported age-related differences in bone formation
would not account for the interval changes in bone
formation and turnover observed in the current study
during treatment with cinacalcet.
In conclusion, high rates of bone formation and several
biochemical markers of high-turnover bone disease decreased
toward normal as PTH was reduced during the treatment of
sHPT with cinacalcet. Twenty-six percent of subjects had
normal bone histology after 12 months of treatment, but
histological abnormalities persisted in many subjects. As
reported previously, adynamic bone can occur if PTH levels
are lowered persistently to values below currently recom-
mended ranges.
MATERIALS AND METHODS
Study subjects
Subjects were eligible for study if they were aged X18 years, had
CKD requiring dialysis, and were willing to undergo a bone biopsy
procedure pending results of biochemical determinations obtained
during screening (vide infra). Laboratory inclusion criteria
were PTH X300 pg/ml, BALP 420.9 ng/ml, and serum calcium
X8.4mg/dl.
Candidates were excluded from study if they had an unstable
medical condition, were pregnant or nursing, had undergone
surgical parathyroidectomy within the previous 3 months, or
had a change in the dose of vitamin D sterol within the past
30 days. Additional exclusion criteria included treatment with
cinacalcet, bisphosphonate, or teriparatide within the previous
30 days.
Study design
This single-arm, multicenter study consisted of 4 phases: a screening
phase lasting up to 3 months, a 20-week dose titration phase,
a 20-week maintenance phase, and a 12-week efficacy assessment
phase (Figure 1). Subjects entered into the study and were treated
with cinacalcet if the bone biopsy obtained during screening showed
changes consistent with hyperparathyroid bone disease using the
following histomorphometric criteria: (1) O.Ar/B.Ar p12% and
BFR/T.Ar 4613 mm2/mm2/day with no peri-trabecular or marrow
fibrosis; (2) O.Ar/B.Ar p12% and BFR/T.Ar 497 mm2/mm2/day
with evidence of fibrosis; or (3) O.Ar/B.Ar 412% and BFR/T.Ar
497 mm2/mm2/day with or without fibrosis. A second bone biopsy
was obtained after 48–52 weeks of treatment or after cinacalcet was
withdrawn for subjects treated for less than 12 but more than
6 months.
Treatment
Treatment with cinacalcet was initiated at a dose of 30mg once daily.
Doses were titrated upwards sequentially at 4-week intervals as
tolerated to 60, 90, or 120mg/day or to a maximum of 180mg/day if
PTH values were X300 pg/ml and serum calcium levels were
X8.0mg/dl. The objective was to achieve and maintain PTH
between 4150 and o300 pg/ml. If PTH was o150 pg/ml, doses
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were reduced to the next lowest dose or withheld for subjects already
receiving the lowest dose of cinacalcet. Cinacalcet also was withheld
if serum calcium was o7.5mg/dl or symptoms of hypocalcemia
developed. Dosing was resumed when PTH levels again exceeded
300 pg/ml.
Concurrent treatment with vitamin D sterols was allowed
throughout the study. Although not permitted during screening,
adjustments to the dose of vitamin D could be made thereafter
based upon measured values for PTH, serum calcium, phosphorus,
and Ca x P. Changes to the doses of calcium supplements and/or
phosphate-binding agents were made at the discretion of the
investigator in accordance with existing standards of clinical
practice.
The study was conducted at 30 sites located in the United States
and Europe in compliance with the Declaration of Helsinki. The
study protocol was reviewed and approved by the Ethics Committee
at each study site, and written informed consent obtained from all
participants.
Bone biopsy and bone histomorphometry
Trans-iliac crest bone biopsies measuring approximately 1 cm in
length and 4–7mm in core diameter were obtained after double
tetracycline labeling using a Bordier trephine in all study
participants during screening. Biopsies were repeated at EOS for
subjects who received at least 6 months of treatment with cinacalcet.
Follow-up biopsy procedures were conducted between weeks 48 and
52 or as soon as possible after treatment was stopped for subjects
who received cinacalcet for at least 6 months.
The method for quantitative histomorphometry of bone
has been described elsewhere.15 Biopsy specimens were fixed in
absolute ethanol and embedded in a methylmethacrylate-
based resin. Undecalcified 5-mm thick sections were stained by the
method of Goldner for quantitative histology to determine static
bone parameters. Ten-mm thick sections were mounted unstained
in 100% glycerol for fluorescence microscopy and visualization
of tetracycline labels. The results were used to calculate dynamic
parameters of bone turnover. All results are reported as measure-
ments in two dimensions using nomenclature established by the
American Society for Bone and Mineral Research.27,28 The various
types of renal osteodystrophy were categorized using histomor-
phometric criteria as reported previously.11,13–15
Bone analysis was performed in the Laboratory of Pathophysiol-
ogy of the University of Antwerp, Belgium, using the semi-
automatic AxioVision system. Key parameters that were assessed
included bone formation rate on tissue area (BFR/T.Ar) (mm2/mm2/
day), mineralization lag time (days), perimeter of active osteoblasts
on osteoid perimeter (Ob.Pm/O.Pm) (%), perimeter of active
osteoclasts on eroded perimeter (Oc.Pm/E.Pm) (%), eroded
perimeter on bone perimeter (E.Pm/B.Pm) (%), double tetracy-
cline-labeled bone perimeter on bone perimeter (dL.Pm/B.Pm),
fibrosis area on tissue area (Fb.Ar/T.Ar) (%), bone area on tissue
area (B.Ar/T.Ar) (%), osteoid area on bone area (O.Ar/B.Ar) (%),
osteoid width (mm), and aluminum stained perimeter on bone
perimeter (%). Osteoid seams less than 2 mm in width were not
included in primary measurements of osteoid width or area.
The various types of renal osteodystrophy were classified using
prespecified criteria as reported elsewhere using several histomor-
phometric parameters including O.Ar/B.Ar, BFR/T.Ar, and Fb.Ar/
T.Ar11,13–15 as follows: normal bone histology: O.Ar/B.Ar p12%,
BFR/T.Ar X97, and p613mm2/mm2/day, without fibrosis; mild
hyperparathyroid bone disease: O.Ar/B.Ar p12%, upper normal or
increased BFR/T.Ar (4613mm2/mm2/day), with 0–5% fibrosis;
severe hyperparathyroid bone disease (osteitis fibrosa): O.Ar/B.Ar
p12%, BFR/T.Ar 4613 mm2/mm2/day, with fibrosis 45%; mixed
uremic osteodystrophy: O.Ar/B.Ar 412%, BFR/T.Ar 497 mm2/
mm2/day, with or without fibrosis (type 1) or O.Ar/B.Ar p12%,
BFR/T.Ar p613mm2/mm2/day, with fibrosis (type 2); adynamic
bone disease: O.Ar/B.Ar p12%, BFR/T.Ar o97 mm2/mm2/day,
without fibrosis; and osteomalacia: O.Ar/B.Ar 412%, BFR/T.Ar
o97 mm2/mm2/day, without fibrosis.
Study end points
Efficacy end points. The primary efficacy end point was the
change from baseline in BFR/T.Ar. Secondary efficacy end points
included (i) change from baseline in Ob.Pm/O.Pm and Oc.Pm/
E.Pm, (ii) change from baseline in E.Pm/B.Pm and Fb.Ar/T.Ar,
(iii) percent change from baseline in PTH, BALP, OC, NTx, and
TRAP, and (iv) percent change from baseline in serum calcium,
phosphorus, and Ca x P concentrations.
Safety end points. Safety end points included the following:
(i) change from baseline in mineralization lag time, osteoid area/
volume, and osteoid width/thickness; (ii) the occurrence of
adynamic bone as defined by osteoid area p12% and BFR/T.Ar
o97 mm2/mm2/day with no evidence of fibrosis; (iii) the nature,
frequency, severity and relationship to treatment of AEs; and (iv)
changes in laboratory parameters.
Biochemical determinations
Plasma PTH (PTH) levels were measured using an immunometric
assay (Advia Centaur) that detects both the full-length hormone
and smaller peptide fragments. Serum calcium and phosphorus
levels were measured by methods reported previously.7 Additional
markers of bone turnover included total alkaline phosphatase (ALP,
colorimetric assay), BALP (two-site Tandem-R-Ostase immuno-
radiometric assay), OC (electro-chemiluminescence immunoassay;
ECLIA), NTx (enzyme-linked immunosorbent assay; ELISA), and
TRAP5b (ELISA). TRAP5b was measured at Pacific Biometrics,
Seattle, whereas the other biochemical analyses were performed
at Covance central laboratories in Indianapolis and Geneva,
Switzerland.
Statistical analysis
The focus of this study was to estimate the change in BFR/T.Ar after
1 year of cinacalcet treatment. All efficacy and bone safety end
points were analyzed using the efficacy data set (subjects who had
both screening and EOS bone biopsies). Biochemical parameters
and baseline bone histomorphometry parameters were further
analyzed using the safety data set (subjects who had received at least
1 dose of cinacalcet). Because of the small number of subjects
enrolled per center, the analyses were based on pooled data from all
study centers. All efficacy and safety end points were summarized
using descriptive statistics such as n, mean, s.d., s.e., median, IQR,
min, and max. Median and IQR are presented because data were not
normally distributed. In exploratory analyses, a one-sample t-test
was used to evaluate the mean change or mean percent change from
baseline in bone histomorphometry and biochemical parameters.
The Wilcoxon signed-rank test was used to compare median values
at baseline and EOS. Because the study was not controlled and
contained only one group, the probability values presented are solely
descriptive in nature and should be considered nominal only.
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Spearman’s correlation was used to examine the relationship
between PTH and bone histomorphometric parameters. Statistical
analyses were performed using SAS version 9.2.
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